Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)

This study is testing a new type of immune cell therapy called dual-target CAR-NK cell therapy in adults with advanced HER2-positive or triple-negative breast cancer (TNBC), two forms of breast cancer that are difficult to treat. The therapy uses engineered natural killer (NK) cells from a donor, customized to target two proteins on the surface of the patient's tumor simultaneously. You may be eligible if you are an adult with advanced or metastatic breast cancer that has progressed despite standard treatments, have measurable disease, an ECOG performance status of 0 or 1, and adequate organ function; tumor tissue will be tested to confirm the right CAR-NK product for your tumor profile. Participation involves receiving a short course of lymphodepleting chemotherapy followed by an infusion of the CAR-NK cells, with close monitoring for safety and response. This summary was prepared using AI to help patients understand this research.